Amicus Therapeutics to Announce Second Quarter 2011 Financial Results on August 8, 2011

John F. Crowley to Return as Full-Time Chairman and Chief Executive Officer on August 4, 2011

CRANBURY, N.J., Aug. 2, 2011 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare diseases, today announced a conference call and live audio webcast on Monday, August 8, 2011 at 5 p.m. ET to discuss financial results for the second quarter ended June 30, 2011.

The call with be hosted by John F. Crowley, who will return as full-time Chairman and Chief Executive Officer on August 4. He will be joined on the call by additional members of the Amicus management team.

Interested participants and investors may access the conference call at 5 p.m. ET by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international).

A live audio webcast can also be accessed via the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 30 days. Web participants are encouraged to go to the web site 15 minutes prior to the start of the call to register, download and install any necessary software.

A telephonic replay of the call will be available for seven days beginning at 8 p.m. ET on August 8, 2011. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); participant code 88345873.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare diseases. The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and diseases of neurodegeneration. Amicus' lead program Amigal(TM) (migalastat HCl) is in Phase 3 for the treatment of Fabry disease.

CONTACT: Investors/Media

Sara Pellegrino

spellegrino@amicustherapeutics.com

(609) 662-5044

Source: Amicus Therapeutics

News Provided by Acquire Media